3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow ABT-072: new trials by email Literature Review of ABT-072 trials Research Report on ABT-072
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) ABT-450, ABT-072, Ribavirin - Hepatitis C, HCV | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 11 | 2010-10-01 | 2015-01-08 |
| A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 ABT-450, ABT-072, ABT-333 - Hepatitis C, HCV | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 74 | 2010-03-01 | 2015-01-08 |
| A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies ABT-072 - Hepatitis C Virus Infection | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 5 | 2009-04-01 | 2013-04-01 |
Hepatitis C (3)
AbbVie (prior sponsor, Abbott) (3)
United States (3) · Puerto Rico (1)
Daniel Cohen, MD (2) · Daniel Cohen (1)